Impaired bile formation and flow (cholestasis) has been associated with increased SphK2/S1P/S1PR2 activation and blocking this pathway with the specific S1PR2 inhibitor, JTE-013, reduced cholestatic liver injury through reduction of total bile acid levels in serum [124]. Here, S1PR2 is linked to cholestasis.